In Brief: Laser Industries
This article was originally published in The Gray Sheet
Executive Summary
Laser Industries: Firm submits investigational device exemption seeking FDA approval to conduct clinical trials of its Sharplan holmium laser in conjunction with a Biosense catheter-based cardiovascular navigation system to perform direct myocardial revascularization (DMR). The minimally invasive procedure intended to relieve angina pain by increasing blood flow to ischemic heart muscles has been undergoing pre-clinical trials for the past year. Laser Industries and Biosense are jointly developing the technology...
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.